Drug Approval | June 27, 2023
USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
One thousand times more soluble than L-cystine at neutral pH
These initiatives aim to improve access to healthcare for rare disease patients
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
The collaboration between CORONA and Ferring will cater to patients across India
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Showcased digital innovations: MyPKFit, SYNAPSE and Athena at the G20 Health Working Group Meeting
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)
Subscribe To Our Newsletter & Stay Updated
